166 related articles for article (PubMed ID: 23072245)
81. Letter: infliximab vs. adalimumab in treating ambulatory perianal fistulising Crohn's disease.
Tursi A; Elisei W; Picchio M; Zampaletta C; Faggiani R; Brandimarte G
Aliment Pharmacol Ther; 2014 Jul; 40(2):218-20. PubMed ID: 24946069
[No Abstract] [Full Text] [Related]
82. Anti-TNF therapy is associated with a reduction in radiation exposure in patients with Crohn's disease.
Aggarwal D; Limdi JK
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):13-9. PubMed ID: 25341058
[TBL] [Abstract][Full Text] [Related]
83. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
Sandborn WJ
Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
[TBL] [Abstract][Full Text] [Related]
84. Adalimumab in the treatment of immune-mediated diseases.
Lapadula G; Marchesoni A; Armuzzi A; Blandizzi C; Caporali R; Chimenti S; Cimaz R; Cimino L; Gionchetti P; Girolomoni G; Lionetti P; Marcellusi A; Mennini FS; Salvarani C
Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):33-48. PubMed ID: 24774505
[TBL] [Abstract][Full Text] [Related]
85. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Rutgeerts P; Van Assche G; Sandborn WJ; Wolf DC; Geboes K; Colombel JF; Reinisch W; ; Kumar A; Lazar A; Camez A; Lomax KG; Pollack PF; D'Haens G
Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
[TBL] [Abstract][Full Text] [Related]
86. Adalimumab-induced psoriatic alopecia/alopecia areata-like reaction in a patient with Crohn's disease.
Toda-Brito H; Lopes L; Soares-Almeida L; Filipe P
Dermatol Online J; 2015 Nov; 21(11):. PubMed ID: 26632930
[TBL] [Abstract][Full Text] [Related]
87. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
[TBL] [Abstract][Full Text] [Related]
88. Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index case.
Goldfeld DA; Verna EC; Lefkowitch J; Swaminath A
Dig Dis Sci; 2011 Nov; 56(11):3386-8. PubMed ID: 21597977
[No Abstract] [Full Text] [Related]
89. Crohn’s disease: towards improving postsurgical outcomes.
Lockett TJ; Kamm MA; De Cruz P; Kirkwood CD
Med J Aust; 2013 Oct; 199(8):524. PubMed ID: 24138368
[No Abstract] [Full Text] [Related]
90. Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.
Selvaraj SA; Chairez E; Wilson LM; Lazarev M; Bass EB; Hutfless S
Syst Rev; 2013 Jul; 2():53. PubMed ID: 23826928
[TBL] [Abstract][Full Text] [Related]
91. Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease.
Hare NC; Hunt DP; Venugopal K; Ho GT; Beez T; Lees CW; Gibson R; Weller B; Satsangi J
QJM; 2014 Jan; 107(1):51-5. PubMed ID: 22240391
[No Abstract] [Full Text] [Related]
92. [Term pregnancy in a patient with Crohn's disease under treatment with adalimumab].
Sánchez Muñoz D; Hoyas Pablos E; Ramírez Martín Del Campo M; Núñez Hospital D; Guerrero Jiménez P
Gastroenterol Hepatol; 2005; 28(7):435. PubMed ID: 16137481
[No Abstract] [Full Text] [Related]
93. Tuberculous monoarthritis after treatment with adalimumab in Crohn's disease.
Martínez-Caselles A; Martínez-Pascual C; Muñoz-Tornero M; Sánchez-Torres A; Carballo-Álvarez F
Rev Esp Enferm Dig; 2012 Mar; 104(3):157-8. PubMed ID: 22449164
[No Abstract] [Full Text] [Related]
94. Hepatitis and pneumonitis during adalimumab therapy in Crohn disease: mind the histoplasmosis!
Pinheiro Bdo V; Delgado Ade A; Chebli JM
Arq Gastroenterol; 2014; 51(1):73-6. PubMed ID: 24760069
[TBL] [Abstract][Full Text] [Related]
95. [Rhomboencephalitis due to Listeria monocytogenes as a complication of Crohn's disease].
Molina J; Núñez O; Beceiro I; Marín I; Pérez-Calle JL
Gastroenterol Hepatol; 2003; 26(7):457-8. PubMed ID: 12887863
[No Abstract] [Full Text] [Related]
96. Bullous pemphigoid in a young male during treatment with adalimumab.
van Ammers M; Lai FYX; Abrahams T; Simpson I; Mar A
Australas J Dermatol; 2021 Feb; 62(1):e155-e156. PubMed ID: 32981042
[No Abstract] [Full Text] [Related]
97. Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab--a paradoxical effect? A case report.
Santos G; Sousa LE; João AM
An Bras Dermatol; 2013; 88(6 Suppl 1):26-8. PubMed ID: 24346872
[TBL] [Abstract][Full Text] [Related]
98. Asymptomatic choroidal tubercle in a patient with Crohn's disease on adalimumab treatment.
Asensio-Sánchez VM; Díaz-Cabanas L; Martín-Prieto A; Haro-Álvarez B
Arch Soc Esp Oftalmol (Engl Ed); 2018 Mar; 93(3):147-150. PubMed ID: 28743416
[TBL] [Abstract][Full Text] [Related]
99. [A case report: feasible treatment of adalimumab for Crohn disease during pregnancy].
Tsujikawa T; Sakai S; Fujii M; Saotome T; Imaeda H; Bamba S; Andoh A; Fujiyama Y
Nihon Shokakibyo Gakkai Zasshi; 2013 Feb; 110(2):243-7. PubMed ID: 23381212
[TBL] [Abstract][Full Text] [Related]
100. Listeria infection in patients using anti-TNFα treatment: Should there be preventive strategies?
Krijthe BP; Hermans MAW; Schurink CAM; van Daele PLA
Eur J Intern Med; 2019 Oct; 68():e15-e16. PubMed ID: 31395466
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
